Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiopoietic cell therapy for chronic ischemic heart failure
2011-001117-13Phase 3Completed
- Sponsor
- Celyad Oncology
- Start
- Jun 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and ischaemic cardiomyopathy (ICM) comparing C3BS-CQR-1 plus standard of care with Sham procedure plus standard of care (2 arms). Primary endpoint: Hierarchical composite efficacy endpoint at 39 weeks. Started Jun 2012; status: completed.
02
Drugs
C-Cure
03
Conditions
heart failure (HF)ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on 2011-001117-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001117-13.